Protective Effect of Mito-TEMPO on Sodium Valproate-Induced Hepatotoxicity in Mice
Abstract
Valproic acid is a broad-spectrum anticonvulsant drug that is also useful for other diseases such as bipolar disorder and migraines. The most important side effect of this drug is hepatotoxicity. Oxidative stress and mitochondrial dysfunction play a role in the pathogenesis of liver toxicity of valproic acid. Mito-TEMPO is an antioxidant-based compound, which is selectively accumulated in mitochondria. The effects of its mitochondrial protection against oxidative damage in various pathologies, such as liver damage, have been observed. The aim of this study was to evaluate the protective effect of Mito-TEMPO on liver toxicity induced by sodium valproate in mice. Animals were divided into five groups and treated intraperitoneally over a 4-week period. Group 1 received normal saline, served as vehicle control, group 2 treated with 12.5 mg/kg of sodium valproate, group 3 was treated with 1 mg/kg of Mito-TEMPO, group 4 received both sodium valproate (12.5 mg/kg) and Mito-TEMPO (1 mg/kg), and group 5 received sodium valproate (12.5 mg/kg), and vitamin E (5 mg/kg) served as a positive control. At the end of the experiment, blood samples were collected by cardiac puncture, and all the animals were killed under ether anesthesia. Biochemical parameters including AST, ALT, ALP, and GGT in serum samples and glutathione (GSH) and malondialdehyde (MDA) contents in liver homogenates were determined. The findings of this study showed that the activity of AST and ALT were significantly lower in the sodium valproate+Mito-TEMPO treated animals as compared to the sodium valproate group (group 2). Furthermore, Mito-TEMPO was able to recover glutathione content (GSH) of liver tissue. The effect of Mito-TEMPO on the activity of ALP and GGT and serum level of MDA was not significant. Taken collectively, Mito-TEMPO has a protective role in sodium valproate hepatotoxicity. Considering the present results, further studies, in view of the potential therapeutic properties of Mito-TEMPO in improving liver damage caused by the use of valproic acid, may lead to the clinical applications of Mito-TEMPO in the treatment of liver disease.
2. Sitarz KS, Elliott HR, Karaman BS, Relton C, Chinnery PF, Horvath R. Valproic acid triggers increased mitochondrial biogenesis in POLG-deficient fibroblasts. Molecular genetics and metabolism. 2014;112(1):57-63.
3. Pandit A, Sachdeva T, Bafna P. Drug-induced hepatotoxicity: a review. J Appl Pharm Sci. 2012;2(5):233-43.
4. Pinkston R, Walker LA. Multiorgan system failure caused by valproic acid toxicity. The American journal of emergency medicine. 1997;15(5):504-6.
5. Powell-Jackson P, Tredger J, Williams R. Hepatotoxicity to sodium valproate: a review. Gut. 1984;25(6):673.
6. Sussman NM, McLain LW. A direct hepatotoxic effect of valproic acid. Jama. 1979;242(11):1173-4.
7. Nau H, Loscher W. Valproic acid and metabolites: pharmacological and toxicological studies. Epilepsia. 1984;25:S14-S22.
8. Silva M, Aires C, Luis P, Ruiter J, IJlst L, Duran M, et al. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. Journal of inherited metabolic disease. 2008;31(2):205-16.
9. Trnka J, Blaikie FH, Smith RA, Murphy MP. A mitochondria-targeted nitroxide is reduced to its hydroxylamine by ubiquinol in mitochondria. Free Radical Biology and Medicine. 2008;44(7):1406-19.
10. Conti M, Morand P, Levillain P, Lemonnier A. Improved fluorometric determination of malonaldehyde. Clinical chemistry. 1991;37(7):1273-5.
11. Lapenna D, Ciofani G, Pierdomenico SD, Giamberardino MA, Cuccurullo F. Reaction conditions affecting the relationship between thiobarbituric acid reactivity and lipid peroxidesin human plasma. Free Radical Biology and Medicine. 2001;31(3):331-5.
12. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. Journal of hypertension. 2000;18(6):655-73.
13. Arroyo S, de la Morena A. Life-threatening adverse events of antiepileptic drugs. Epilepsy research. 2001;47(1-2):155-74.
14. Ahmed SN, Siddiqi ZA. Antiepileptic drugs and liver disease. Seizure. 2006;15(3):156-64.
15. Valko M, Morris H, Cronin M. Metals, toxicity and oxidative stress. Current medicinal chemistry. 2005;12(10):1161-208.
16. Prakash M, Gunasekaran G, Elumalai K. Effect of earthworm powder on antioxidant enzymes in alcohol induced hepatotoxic rats. Eur Rev Med Pharmacol Sci. 2008;12(4):237-43.
17. Dreifuss F, Santilli N, Langer D, Sweeney K, Moline K, Menander K. Valproic acid hepatic fatalities: a retrospective review. Neurology. 1987;37(3):379-.
18. Dikalova AE, Bikineyeva AT, Budzyn K, Nazarewicz RR, McCann L, Lewis W, et al. Therapeutic targeting of mitochondrial superoxide in hypertension. Circulation research. 2010;107(1):106.
19. Liang HL, Sedlic F, Bosnjak Z, Nilakantan V. SOD1 and MitoTEMPO partially prevent mitochondrial permeability transition pore opening, necrosis, and mitochondrial apoptosis after ATP depletion recovery. Free radical biology & medicine. 2010;49(10):1550-60.
20. Liu M, Liu H, Dudley SC, Jr. Reactive oxygen species originating from mitochondria regulate the cardiac sodium channel. Circulation research. 2010;107(8):967-74.
21. Ni R, Cao T, Xiong S, Ma J, Fan G-C, Lacefield JC, et al. Therapeutic inhibition of mitochondrial reactive oxygen species with mito-TEMPO reduces diabetic cardiomyopathy. Free Radical Biology and Medicine. 2016;90:12-23.
22. Du K, Farhood A, Jaeschke H. Mitochondria-targeted antioxidant Mito-Tempo protects against acetaminophen hepatotoxicity. Archives of toxicology. 2017;91(2):761-73.
23. Lu X, Zhang Y, Bai H, Liu J, Li J, Wu B. Mitochondria-targeted antioxidant MitoTEMPO improves the post-thaw sperm quality. Cryobiology. 2018;80:26-9.
| Files | ||
| Issue | Vol 58, No 7 (2020) | |
| Section | Original Article(s) | |
| DOI | https://doi.org/10.18502/acta.v58i7.4425 | |
| Keywords | ||
| Mito-TEMPO Valproic acid Hepatotoxicity | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
